Moderna’s Rocky Road: Can the Biotech Giant Rebound?
A Steep Decline
Moderna’s share price has taken a drastic hit, plummeting 58% in 2024, making it one of the worst performers in the S&P 500 index. The biotech company, known for its groundbreaking mRNA-based vaccines, has struggled to maintain sales of its COVID-19 vaccine and has faced sluggish market adoption of its new respiratory syncytial virus (RSV) shot.
Weak Sales and Slashed Guidance
The company’s revenue has declined 44% year over year, with a mere $10 million in sales of its new RSV vaccine. Despite efforts to reduce costs and improve financial efficiency, Moderna’s year-to-date per-share earnings loss of $6.37 is a far cry from its previous year’s loss. The persistent top-line weakness continues to weigh heavily on the stock.
A Revised Forecast
At a recent investor conference, Moderna revised its 2025 sales forecast downward, projecting full-year revenue of between $1.5 billion and $2.5 billion, a $1 billion reduction from its previous forecast. Wall Street analysts expect the company to remain unprofitable for the foreseeable future.
A Pipeline of Promise
Despite the challenges, Moderna’s extensive pipeline of therapeutics in clinical trials offers a glimmer of hope. The company is advancing its late-stage candidate pipeline, including vaccines for norovirus and cytomegalovirus (CMV), as well as a promising mRNA-4157, being studied in collaboration with Merck, which shows potential across multiple cancerous tumor types.
A Roadmap to Recovery
Moderna’s strategy in 2025 focuses on maintaining its COVID-19 immunization market share while advancing its pipeline. The company aims to secure 10 product approvals within the next three years, targeting a compound annual growth rate (CAGR) for revenue exceeding 25% between 2026 and 2028. With a robust balance sheet to support its objectives, Moderna may be poised for a turnaround.
Is Moderna Stock a Buy?
While Moderna’s proven leadership in mRNA technology is attractive, securing a second blockbuster drug will be crucial for the company’s sustainability. Given the poor sales trajectory and numerous uncertainties about the company’s near-term prospects, it’s essential to approach with caution. Investors may find more compelling opportunities elsewhere.
Leave a Reply